(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.97%) $80.00
(5.73%) $2.64
(1.44%) $2 419.80
(6.36%) $31.78
(2.18%) $1 094.70
(-0.02%) $0.920
(-0.18%) $10.68
(-0.27%) $0.787
(0.19%) $91.05
Quarter results tomorrow
(bmo 2024-05-20)
Expected move: +/- 8.33%
Live Chart Being Loaded With Signals
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain...
Stats | |
---|---|
本日の出来高 | 45 224.00 |
平均出来高 | 64 693.00 |
時価総額 | 11.20M |
EPS | $0 ( 2024-03-29 ) |
次の収益日 | ( $-0.790 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.480 |
ATR14 | $0.0300 (1.72%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Werner Milton H. | Buy | 45 000 | Stock Option (right to buy) |
2024-04-01 | Lees-rolfe Garth | Buy | 90 000 | Stock Option (right to buy) |
2024-04-01 | Lees-rolfe Garth | Sell | 5 834 | Stock Option (right to buy) |
2023-06-30 | Berman Dennis N | Buy | 6 667 | Stock Option (right to buy) |
2023-06-30 | Dion Gisele | Buy | 6 667 | Stock Option (right to buy) |
INSIDER POWER |
---|
96.37 |
Last 62 transactions |
Buy: 1 923 769 | Sell: 2 120 717 |
ボリューム 相関
Inhibikase Therapeutics, 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Inhibikase Therapeutics, 相関 - 通貨/商品
Inhibikase Therapeutics, 財務諸表
Annual | 2023 |
収益: | $260 500 |
総利益: | $83 102.00 (31.90 %) |
EPS: | $-3.57 |
FY | 2023 |
収益: | $260 500 |
総利益: | $83 102.00 (31.90 %) |
EPS: | $-3.57 |
FY | 2022 |
収益: | $123 440 |
総利益: | $116 717 (94.55 %) |
EPS: | $-4.26 |
FY | 2021 |
収益: | $3.10M |
総利益: | $3.10M (100.00 %) |
EPS: | $-0.810 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Inhibikase Therapeutics,
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。